[Prevention of thromboembolism with antiaggregants (author's transl)].
Experimental investigations have shown that antiaggregants affect the size rather than the rate of venous thrombosis, while clinical trials with prophylactic acetylsalicylic acid have indicated primarily a reduced incidence of pulmonary embolism. Current experiences with acetylsalicylic acid in combination with dipyridamole or low-dose heparin suggest that the incidence of pathology diagnosed by 125I-fibrinogen and of deep vein thrombosis is equally reduced.
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D002415:Cats; D004176:Dipyridamole / Q000627:therapeutic use; D004285:Dogs; D004357:Drug Synergism; D006493:Heparin / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits; D051381:Rats; D013923:Thromboembolism / Q000097:blood / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000097:blood / Q000517:prevention & control
D000925:Anticoagulants; D004176:Dipyridamole; D006493:Heparin; D001241:Aspirin
Medikamentöse Thromboembolie-Prophylaxe mit Aggregationshemmern.